Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae.

Matrone G, Mullins JJ, Tucker CS, Denvir MA.

Cell Cycle. 2016 Nov 16;15(22):3060-3069. Epub 2016 Oct 7.

2.

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.

Albert TK, Rigault C, Eickhoff J, Baumgart K, Antrecht C, Klebl B, Mittler G, Meisterernst M.

Br J Pharmacol. 2014 Jan;171(1):55-68. doi: 10.1111/bph.12408.

3.

Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.

Schmerwitz UK, Sass G, Khandoga AG, Joore J, Mayer BA, Berberich N, Totzke F, Krombach F, Tiegs G, Zahler S, Vollmar AM, Fürst R.

Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):280-8. doi: 10.1161/ATVBAHA.110.213934. Epub 2010 Nov 18.

PMID:
21088252
4.

The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation.

Oqani RK, Kim HR, Diao YF, Park CS, Jin DI.

BMC Dev Biol. 2011 Jun 3;11:33. doi: 10.1186/1471-213X-11-33.

5.

Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo.

Hoodless LJ, Lucas CD, Duffin R, Denvir MA, Haslett C, Tucker CS, Rossi AG.

Sci Rep. 2016 Nov 11;5:36980. doi: 10.1038/srep36980.

6.

CDK9 inhibition strategy defines distinct sets of target genes.

Garriga J, Graña X.

BMC Res Notes. 2014 May 16;7:301. doi: 10.1186/1756-0500-7-301.

7.

CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.

Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S.

Int J Cancer. 2012 Mar 1;130(5):1216-26. doi: 10.1002/ijc.26127. Epub 2011 Jun 21.

8.

Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos.

McAleer MF, Duffy KT, Davidson WR, Kari G, Dicker AP, Rodeck U, Wickstrom E.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):546-51. Epub 2006 Aug 14.

PMID:
16904844
9.

Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.

Caracciolo V, Laurenti G, Romano G, Carnevale V, Cimini AM, Crozier-Fitzgerald C, Gentile Warschauer E, Russo G, Giordano A.

Cell Cycle. 2012 Mar 15;11(6):1202-16. doi: 10.4161/cc.11.6.19663. Epub 2012 Mar 15.

PMID:
22391209
10.

CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D.

Mol Endocrinol. 2010 Dec;24(12):2267-80. doi: 10.1210/me.2010-0238. Epub 2010 Oct 27.

12.

Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.

Wang K, Hampson P, Hazeldine J, Krystof V, Strnad M, Pechan P, M J.

PLoS One. 2012;7(1):e30128. doi: 10.1371/journal.pone.0030128. Epub 2012 Jan 19.

13.

CDK9 and its repressor LARP7 modulate cardiomyocyte proliferation and response to injury in the zebrafish heart.

Matrone G, Wilson KS, Maqsood S, Mullins JJ, Tucker CS, Denvir MA.

J Cell Sci. 2015 Dec 15;128(24):4560-71. doi: 10.1242/jcs.175018. Epub 2015 Nov 5.

14.

Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.

Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS.

Mol Cancer Ther. 2012 Nov;11(11):2321-30. doi: 10.1158/1535-7163.MCT-12-0578. Epub 2012 Sep 10.

15.

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.

Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A.

J Med Chem. 2016 Oct 13;59(19):8667-8684. Epub 2016 Jun 3.

16.

Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA.

Burger K, Mühl B, Rohrmoser M, Coordes B, Heidemann M, Kellner M, Gruber-Eber A, Heissmeyer V, Strässer K, Eick D.

J Biol Chem. 2013 Jul 19;288(29):21173-83. doi: 10.1074/jbc.M113.483719. Epub 2013 Jun 6.

17.

The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.

Hou T, Ray S, Brasier AR.

J Biol Chem. 2007 Dec 21;282(51):37091-102. Epub 2007 Oct 23.

18.

The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.

Ambrosini G, Seelman SL, Qin LX, Schwartz GK.

Cancer Res. 2008 Apr 1;68(7):2312-20. doi: 10.1158/0008-5472.CAN-07-2395.

19.

Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.

Han Y, Zhao S, Gong Y, Hou G, Li X, Li L.

Oncotarget. 2016 Jan 12;7(2):1854-62. doi: 10.18632/oncotarget.6443.

20.

Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.

Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, Graña X.

Gene. 2007 Dec 15;405(1-2):65-78. Epub 2007 Sep 19.

Supplemental Content

Support Center